title: Cytarabine preferentially induces mutation at specific sequences in the genome which are identifiable in relapsed acute myeloid leukaemia.
authors.affiliation: Newcastle Cancer Centre, Northern Institute for Cancer Research, Paul O'Gorman Building, Newcastle University, Newcastle-upon-Tyne, UK.
authors.forename: S E
authors.initials: SE
authors.lastname: Fordham
authors.affiliation: Newcastle Cancer Centre, Northern Institute for Cancer Research, Paul O'Gorman Building, Newcastle University, Newcastle-upon-Tyne, UK.
authors.forename: M
authors.initials: M
authors.lastname: Cole
authors.affiliation: Newcastle Cancer Centre, Northern Institute for Cancer Research, Paul O'Gorman Building, Newcastle University, Newcastle-upon-Tyne, UK.
authors.forename: J A
authors.initials: JA
authors.lastname: Irving
authors.affiliation: Newcastle Cancer Centre, Northern Institute for Cancer Research, Paul O'Gorman Building, Newcastle University, Newcastle-upon-Tyne, UK.
authors.forename: J M
authors.initials: JM
authors.lastname: Allan
mesh_terms: D000465:Algorithms; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects; D045744:Cell Line, Tumor; D003561:Cytarabine / Q000009:adverse effects / Q000737:chemistry*; D004252:DNA Mutational Analysis; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D009010:Monte Carlo Method; D009154:Mutation; D009364:Neoplasm Recurrence, Local / Q000235:genetics*; D012074:Remission Induction
chemical_list: D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine